Biomarkers /
PDGFB
Back to Biomarkers List
Overview
Platelet-derived growth factor beta polypeptide (PDGFB) is a gene that encodes a protein that functions as a mitogenic factor for cells of mesenchymal origin. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
PDGFB is altered in 0.08% of all cancers with dermatofibrosarcoma protuberans, conventional glioblastoma multiforme, high grade ovarian serous adenocarcinoma, colon adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in PDGFB are PDGFB Mutation (0.16%), PDGFB Fusion (0.03%), PDGFB-COL1A1 Fusion (0.02%), PDGFB C13Y (0.02%), and PDGFB R142H (0.18%) [3].
Clinical Trials
Significance of PDGFB in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
